###begin article-title 0
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
Association between LTA, TNF and AGER Polymorphisms and Late Diabetic Complications
###end article-title 0
###begin p 1
Conceived and designed the experiments: EL CA. Performed the experiments: EL EB. Analyzed the data: EL. Contributed reagents/materials/analysis tools: LG CC CA EA. Wrote the paper: LG EL CA EB EA.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 223 226 223 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 239 242 237 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 258 262 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
Several candidate genes on the short arm of chromosome 6 including the HLA locus, TNF, LTA and AGER could be associated with late diabetic complications. The aim of our study was therefore to explore whether polymorphisms (TNF -308 G-->A, LTA T60N C-->A and AGER -374 T-->A) in these genes alone or together (as haplotypes) increased the risk for diabetic complications.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 252 255 252 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 260 264 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 304 312 304 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 503 506 503 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 614 618 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 987 990 987 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 387 395 <span type="species:ncbi:9606">patients</span>
###xml 720 728 <span type="species:ncbi:9606">patients</span>
###xml 831 839 <span type="species:ncbi:9606">patients</span>
###xml 941 949 <span type="species:ncbi:9606">patients</span>
###xml 1136 1144 <span type="species:ncbi:9606">patients</span>
The studied polymorphisms were genotyped in 742 type 1 and 2957 type 2 diabetic patients as well as in 206 non-diabetic control subjects. The Haploview program was used to analyze putative linkage disequilibrium between studied polymorphisms. The TNF, LTA and AGER polymorphisms were associated with the HLA-DQB1 risk genotypes. The AGER -374 A allele was more common in type 1 diabetic patients with than without diabetic nephropathy (31.2 vs. 28.4%, p = 0.007). In a logistic regression analysis, the LTA but not the AGER polymorphism was associated with diabetic nephropathy (OR 2.55[1.11-5.86], p = 0.03). The AGER -374 A allele was associated with increased risk of sight threatening retinopathy in type 2 diabetic patients (1.65[1.11-2.45], p = 0.01) and also with increased risk for macrovascular disease in type 1 diabetic patients (OR 2.05[1.19-3.54], p = 0.01), but with decreased risk for macrovascular disease in type 2 diabetic patients (OR 0.66[0.49-0.90], p = 0.009). The TNF A allele was associated with increased risk for macrovascular complications in type 2 (OR 1.53 [1.04-2.25], p = 0.03, but not in type 1 diabetic patients.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 296 304 296 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
The association between diabetic complications and LTA, TNF and AGER polymorphisms is complex, with partly different alleles conferring susceptibility in type 1 and type 2 diabetic patients. We can not exclude the possibility that the genes are part of a large haplotype block that also includes HLA-DQB1 risk genotypes.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 84 87 84 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Navarro1">[1]</xref>
###xml 341 344 333 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Joussen1">[2]</xref>
###xml 346 349 338 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Joussen2">[3]</xref>
###xml 472 475 460 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Gustavsson1">[4]</xref>
###xml 546 549 534 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-DallaVestra1">[5]</xref>
###xml 659 662 647 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Libby1">[6]</xref>
###xml 914 917 879 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Makhatadze1">[7]</xref>
###xml 995 998 952 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1067 1070 1020 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 1072 1075 1025 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Knight1">[8]</xref>
###xml 1228 1231 1181 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Vlassara1">[9]</xref>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
The etiology of diabetic complications is complex, and inflammation may play a role [1]. The mRNA expression for pro-inflammatory cytokines such as IL-1 and Tumor Necrosis Factor Alpha (TNF-alpha) is increased in the retina and animal studies suggest that inhibition of TNF-alpha has beneficial effects in prevention of diabetic retinopathy [2], [3]. Recently, we have shown that type 1 diabetic patients with proliferative retinopathy have increased levels of TNF- alpha [4]. Similarly, inflammatory markers are elevated in diabetic nephropathy [5] and inflammation is associated with development of macrovascular complications such as myocardial infarction [6]. TNF-alpha and lymphotoxin-alpha (LT-alpha, also known as TNF-beta) belong to the same TNF family and are encoded by the same gene cluster. TNF-alpha is mainly produced by activated macrophages and LT-alpha by T, B and natural killer cell lymphocytes [7]. Promoter variants -308A-->G and -238G-->A in the gene coding for TNF-alpha (TNF) affect transcriptional regulation of the gene coding for LT-alpha (LTA) [8]. The receptor for advanced glycation end products (RAGE) is also mainly considered as an intracellular signal and transducer or proinflammatory peptide [9].
###end p 9
###begin p 10
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 5 8 5 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Dyck1">[10]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Agardh1">[11]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Dahlen1">[12]</xref>
###xml 500 504 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 648 652 646 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Lindholm1">[13]</xref>
###xml 704 708 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 753 757 751 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-PetterssonFernholm1">[14]</xref>
###xml 804 808 802 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 869 872 867 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 877 880 875 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
LTA, TNF and the gene encoding for RAGE (AGER) are all located within the MHC complex on the short arm of chromosome 6. The HLA locus is among the most polymorphic in the human genome. Some studies have suggested a direct role of HLA in development of diabetic nephropathy [10], retinopathy [11] and macrovascular disease [12]. Since this region also harbours a variety of other genes involved in inflammation, the results could also reflect variation in other genes than HLA. We have recently shown AGER -374T-->A polymorphism to be associated with diabetic nephropathy and possibly with retinopathy in type 1, but not in type 2 diabetic patients [13]. The results concerning the risk allele (A) in the AGER gene were in conflict with a previous study [14], and a possible explanation could be that the AGER gene is in linkage disequilibrium with other genes, such as TNF and LTA.
###end p 10
###begin p 11
###xml 13 16 13 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Manchanda1">[15]</xref>
###xml 95 99 95 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Kumaramanickavel1">[16]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Um1">[17]</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Bernard1">[18]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Ozaki1">[19]</xref>
###xml 389 392 387 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 605 609 603 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Asselbergs1">[20]</xref>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
Variation in TNF and LTA genes has been associated with diabetic nephropathy [15], retinopathy [16] as well as with cardiovascular and cerebrovascular disease [17], [18]. A large genome-scan in Japanese patients identified a susceptibility locus for myocardial infarction on chromosome 6p21 [19], especially the 256A-->G and T60N (also referred to as T26N in some studies) variants in the LTA gene, were associated with myocardial infarction. However, a recent, rather large study from USA could neither confirm the association with myocardial infarction, nor the association with inflammatory biomarkers [20].
###end p 11
###begin p 12
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 52 60 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Li1">[21]</xref>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 154 162 152 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 178 182 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Lindholm1">[13]</xref>
###xml 289 293 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 326 330 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Laki1">[22]</xref>
The TNF/LTA locus is in linkage disequilibrium with HLA-DQB1[21] and we have previously shown that the AGER -374T-->A polymorphism is associated with the HLA-DQB1 risk genotypes [13]. In a recent study the HLA 8.1 ancestral haplotype was shown to be strongly linked to the C allele of the AGER -429T-->C promoter polymorphism [22]. Our aim was to study whether variants in these genes form a putative haplotype associated with increased risk of diabetic nephropathy, retinopathy and macrovascular disease.
###end p 12
###begin title 13
Results
###end title 13
###begin p 14
###xml 111 118 111 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t001">Table 1</xref>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 152 155 152 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 192 199 192 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t002">Table 2</xref>
###xml 424 427 424 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 440 443 440 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 459 463 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 509 512 509 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 514 517 514 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 522 526 522 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 660 663 660 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 665 668 665 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 673 677 673 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 717 725 717 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 737 744 737 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t003">Table 3</xref>
###xml 775 778 775 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 838 846 838 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 945 948 945 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1004 1012 1004 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 1065 1069 1065 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 1129 1137 1129 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 1290 1293 1290 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 1295 1298 1295 1298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1303 1307 1303 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 1415 1418 1415 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1470 1471 1470 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1484 1488 1484 1488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 1525 1528 1525 1528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 1552 1553 1552 1553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1572 1575 1572 1575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1599 1600 1599 1600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 580 588 <span type="species:ncbi:9606">patients</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
###xml 811 819 <span type="species:ncbi:9606">patients</span>
###xml 979 987 <span type="species:ncbi:9606">patients</span>
###xml 1102 1110 <span type="species:ncbi:9606">patients</span>
###xml 1247 1255 <span type="species:ncbi:9606">patients</span>
###xml 1352 1360 <span type="species:ncbi:9606">patients</span>
###xml 1381 1389 <span type="species:ncbi:9606">patients</span>
###xml 1629 1637 <span type="species:ncbi:9606">patients</span>
Type 2 diabetic patients were older and had higher BMI than type 1 diabetic patients or non-diabetic controls (Table 1). Genotype distributions of LTA, TNF and AGER polymorphisms are shown in Table 2. All three variants deviated from the Hardy-Weinberg equilibrium in type 1, but neither in type 2 diabetic patients nor in non-diabetic controls. In type 1 diabetic patients there was an excess of heterozygous patients with LTA (p<0.0002), TNF (p = 0.02) and AGER (p = 0.008). The genotype frequencies of the LTA, TNF and AGER polymorphisms were different between type 1 diabetic patients and controls and also between type 1 and type 2 diabetic patients. The LTA, TNF and AGER polymorphisms were associated with the HLA-DQB1 genotypes (Table 3). The minor allele (A) of the LTA polymorphism was less common in patients with than without HLA-DQB1 genotypes risk genotypes (37.2 vs. 43.9%, p = 0.0001). No difference in allele frequencies of the TNF polymorphism was seen between patients with or without HLA-DQB1 risk genotypes, however the minor allele (A) of the AGER polymorphism was more common in patients with than without HLA-DQB1 risk alleles (34.5 vs. 22.9%), p<0.000001). Because of lack of Hardy-Weinberg equilibrium in type 1 diabetic patients, we could not confirm whether the LTA, TNF and AGER polymorphisms were in LD in type 1 diabetic patients. In type 2 diabetic patients and controls the LTA and TNF polymorphisms were in LD (D' = 1.00 [0.99-1.00] , r2 = 0.4). The AGER polymorphism was neither in LD with LTA (D' 0.13 [0.06-0.20], r2 = 0.004) nor with TNF (D' 0.36 [0.23-0.43], r2 = 0.009) in type 2 diabetic patients.
###end p 14
###begin title 15
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of the patients and non-diabetic control subjects.
###end title 15
###begin p 16
p<0.000001.
###end p 16
###begin p 17
###xml 37 45 <span type="species:ncbi:9606">patients</span>
p = 0.01. Type 1 and type 2 diabetic patients vs. controls.
###end p 17
###begin title 18
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 46 49 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 65 69 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
Genotype frequencies (%) of LTA T60N (C-->A), TNF -308 G-->A and AGER -374 T-->A polymorphism in nondiabetic controls and in type 1 and type 2 diabetic patients.
###end title 18
###begin p 19
The uncorrected p-value refers to differences in genotype frequencies (CC vs CA/AA, GG vs. GA/AA and TT vs. TA/AA). Corrected p-value refers to differences in allele frequencies after 100 000 permutations (haploview).
###end p 19
###begin title 20
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Minor allele frequencies according to HLA-DQB1 genotype in type 1 diabetic patients.
###end title 20
###begin p 21
Numbers are number of alleles N (%).
###end p 21
###begin p 22
P<0.000001, Chi-Square = 94.2 df = 11.
###end p 22
###begin p 23
P<0.000001, Chi-Square = 196.3,df = 11.
###end p 23
###begin p 24
P<0.000001, Chi-Square = 98.8,df = 11.
###end p 24
###begin p 25
Expected value <5 in type 1 diabetes. These genotypes were pooled in the statistical analysis. X could mean either a homozygous allele or any allele other than 02, 0301, 0302, 0602 or 0604.
###end p 25
###begin title 26
Diabetic Nephropathy
###end title 26
###begin p 27
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAGE</italic>
###xml 191 198 189 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t004">Table 4</xref>
###xml 313 316 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 332 335 328 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 600 607 596 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t004">Table 4</xref>
###xml 672 674 668 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
###xml 778 786 774 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 839 842 835 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 973 982 969 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002546-g001">Figure 1a</xref>
###xml 1018 1026 1014 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 1047 1050 1043 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 1052 1055 1048 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1060 1064 1056 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 1169 1172 1165 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 1174 1177 1170 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1182 1186 1178 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 1276 1285 1272 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002546-g001">Figure 1b</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 387 395 <span type="species:ncbi:9606">patients</span>
###xml 552 560 <span type="species:ncbi:9606">patients</span>
###xml 876 884 <span type="species:ncbi:9606">patients</span>
###xml 1004 1012 <span type="species:ncbi:9606">patients</span>
###xml 1266 1274 <span type="species:ncbi:9606">patients</span>
Type 1 diabetic patients with diabetic nephropathy had a higher frequency of the RAGE -374 A allele (31.2%) compared to those who maintained normoalbuminuria >/=10 years (28.4%) (P = 0.007) (Table 4) and the difference remained even after correction for multiple comparisons (p = 0.02). The allele frequencies of TNF -308 G-->A and LTA T60N polymorphisms were similar in type 1 diabetic patients with and without diabetic nephropathy. No differences in allele or haplotype frequencies of the studied polymorphisms were observed between type 2 diabetic patients with and without diabetic nephropathy (Table 4). In a logistic regression analysis with age, duration, BMI, HbA1c, systolic and diastolic blood pressure, sex, previous or current smoking and studied polymorphisms and HLA-DQB1 risk genotypes as independent variables, having the LTA T60N A allele in type 1 diabetic patients was associated with increased risk diabetic nephropathy (OR 2.55[1.11-5.86],p = 0.03), (Figure 1a). In type 2 diabetic patients, the HLA-DQB1 risk allele but not LTA, TNF and AGER polymorphisms was associated with increased risk for diabetic nephropathy (1.75 [1.05-2.94], p = 0.03). LTA, TNF and AGER polymorphisms were not associated with diabetic nephropathy in type 2 diabetic patients (Figure 1b).
###end p 27
###begin title 28
###xml 83 86 83 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 101 104 99 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 117 121 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 151 159 145 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Logistic regression analysis in type 1 (1a) and type 2 (1b) diabetic patients with LTA T60N (C-->A), TNF -308 G-->A, AGER -374 T-->A polymorphisms and HLA-DQB1 risk genotypes as independent and diabetic complication as dependent variable.
###end title 28
###begin p 29
Age, systolic and diastolic blood pressure, sex, previous/current smoking are included in all models. BMI is included in the models for nephropathy and macrovascular disease, duration in the models for nephropathy and retinopathy and age at diagnosis in the model for macrovascular disease.
###end p 29
###begin title 30
###xml 23 26 23 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 41 44 39 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 59 63 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
Allelic association of LTA T60N (C-->A), TNF -308G-->A and AGER -374 T-->A polymorphism with diabetic nephropathy, retinopathy and macrovascular complications.
###end title 30
###begin p 31
The uncorrected p-value refers to differences in allele frequencies. Corrected p-value refers to differences in allele frequencies using after 100 000 permutations (Haploview).
###end p 31
###begin title 32
Diabetic retinopathy
###end title 32
###begin p 33
###xml 198 205 198 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t004">Table 4</xref>
###xml 265 267 265 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
###xml 378 386 378 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 539 542 539 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 544 547 544 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 552 556 552 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 655 664 655 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002546-g001">Figure 1a</xref>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 811 820 811 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002546-g001">Figure 1b</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
The allele (or haplotype) frequencies of the studied polymorphisms did not differ between patients with and without sight-threatening retinopathy, neither in type 1 nor in type 2 diabetic patients (Table 4). In a logistic regression analysis with age, duration, HbA1c, systolic and diastolic blood pressure, sex, current/previous smoking and genotypes as independent variables, HLA-DQB1 risk genotype was associated with decreased risk for sight-threatening retinopathy in type 1 diabetic patients (0.66[0.44-0.99], p = 0.04). In contrast LTA, TNF and AGER polymorphisms were not associated with sight-threatening retinopathy in type 1 diabetic patients (Figure 1a). In type 2 diabetic patients the AGER A allele was associated with increased risk for sight-threatening retinopathy (1.65[1.11-2.45], p = 0.01) (Figure 1b).
###end p 33
###begin title 34
Macrovascular complications
###end title 34
###begin p 35
###xml 99 102 99 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 191 198 191 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t004">Table 4</xref>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
Type 1 diabetic patients with a history of macrovascular complications had higher frequency of the LTA A allele than patients without macrovascular complications (52.7% vs. 44.8%, p = 0.03) (Table 4). The allele frequencies of the TNF and AGER polymorphisms did not differ between type 1 diabetic patients with and without history of macrovascular disease.
###end p 35
###begin p 36
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 158 167 158 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002546-g001">Figure 1a</xref>
###xml 202 210 202 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 606 615 606 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002546-g001">Figure 1a</xref>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
In a logistic regression analysis, the AGER - 374 A allele was associated with increased risk for macrovascular complications (OR 2.05[1.19-3.54], p = 0.01), Figure 1a) in type 1 diabetic patients. The HLA-DQB1 risk genotype was associated with decreased risk for macrovascular disease in type 1 diabetic patients (OR 0.49[0.28-0.86], p = 0.01). The gene-gene interaction was tested in a separate logistic regression model (assuming a dominant model) by adding a term (AGER)x(HLA risk genotype). The gene-gene interaction term was however not significant and was therefore not included in the final model (Figure 1a).
###end p 36
###begin p 37
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 243 250 243 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t004">Table 4</xref>
###xml 359 366 359 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002546-t004">Table 4</xref>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 397 400 397 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 553 556 553 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 738 747 738 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002546-g001">Figure 1b</xref>
###xml 996 1005 996 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002546-g001">Figure 1b</xref>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
In type 2 diabetic patients the frequency of both TNF -308 A allele and AGER -374 T allele genotype was higher in patients with than without macrovascular complications (21.6% vs. 18.1%, p = 0.003 and 76.7% vs. 73.5%, p = 0.03, respectively) (Table 4), the significance of difference in frequency of AGER -374 polymorphism did not stand multiple comparisons (Table 4). The AA haplotype of TNF and LTA was more common in type 2 diabetic patients with than without macrovascular disease (21.5% vs. 18.1%, p = 0.003). In a logistic regression analysis the TNF -308 A allele (OR 1.53[1.04-2.25], p = 0.03) was associated with increased and the AGER -374 A allele with decreased risk (OR 0.66[0.49-0.90], p = 0.009) for macrovascular disease (Figure 1b). The gene-gene interaction was tested in a separate logistic regression model (assuming a dominant model) by adding a term (AGER)x(TNF). The gene-gene interaction term was however not significant and was therefore not included in the final model (Figure 1b).
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 126 134 126 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 233 236 233 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 238 241 238 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 786 790 786 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Noble1">[23]</xref>
###xml 946 950 946 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Single1">[24]</xref>
###xml 989 992 989 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 994 997 994 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1002 1006 1002 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 1201 1205 1201 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 1340 1344 1338 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Laki1">[22]</xref>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 777 785 <span type="species:ncbi:9606">patients</span>
###xml 937 945 <span type="species:ncbi:9606">patients</span>
###xml 1070 1078 <span type="species:ncbi:9606">patients</span>
The key finding of the present study was that the polymorphisms in the TNF, LTA and AGER genes were associated with high risk HLA-DQB1 alleles on chromosome 6p21 and that they influenced the risk for late diabetic complications. The TNF, LTA and AGER alleles were in Hardy-Weinberg equilibrium in as well in non-diabetic controls as in type 2 diabetic patients. In type 1 diabetic patients all of the studied polymorphisms deviated from Hardy-Weinberg equilibrium having excess of heterozygous alleles. This is well in line with previous observations of a synergistic effect of the DR3 and DR4 haplotypes DRB1*0301-DQA1*0501-DQB1*0201 and DRB1*0401-DQA1*0301-DQB1*0302 which are strongly associated with type 1 diabetes thus leading to excess of heterozygous versus homozygous patients [23]. Deviation from Hardy-Weinberg equilibrium will influence the estimated haplotype frequencies especially in a situation with excess of homozygous patients [24]. Therefore, we could not test whether LTA, TNF and AGER polymorphisms are in linkage disequilibrium in type 1 diabetic patients as suggested by Laki et. al. who recently showed that the HLA 8.1 ancestral haplotype (8.1 AH) was strongly linked to the AGER -429T-->C polymorphism and the AGER -429 allele should therefore be considered as candidate member of the HLA 8.1 ancestral haplotype [22].
###end p 39
###begin p 40
###xml 77 80 77 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 447 455 447 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 498 501 498 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 606 610 606 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 874 877 874 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 882 886 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 581 589 <span type="species:ncbi:9606">patients</span>
###xml 753 761 <span type="species:ncbi:9606">patients</span>
The association patterns between diabetic complications and polymorphisms in LTA, TNF, AGER and HLA was complex and none of the studied polymorphism was associated with all diabetic complications in either type 1 or type 2 diabetic patients. For example, the A allele of the AGER -374 polymorphism was more common in type 1 diabetic patients with than without diabetic nephropathy. In a regression model however, when all of the polymorphisms and HLA-DQB1 risk genotype were included in the model, LTA rather than AGER was a risk factor for diabetic nephropathy in type 1 diabetic patients. Similarly, the AGER A allele was associated with increased risk for sight-threatening retinopathy but decreased risk for macrovascular disease in type 2 diabetic patients which raises a question, whether this could represent a survival bias because of the strong association between TNF and AGER polymorphisms and macrovascular disease.
###end p 40
###begin p 41
###xml 350 353 350 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 355 358 355 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAGE</italic>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-PetterssonFernholm1">[14]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Asselbergs1">[20]</xref>
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Hudson1">[25]</xref>
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Zeggini1">[30]</xref>
###xml 682 686 682 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Zeggini1">[30]</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 663 671 <span type="species:ncbi:9606">patients</span>
###xml 733 741 <span type="species:ncbi:9606">patients</span>
The lack of association in type 1 diabetic patients could of course be due to small sample size. Another possible source of bias could be population stratification due to ethically diverse samples, which is not very likely given the fact that all patients were Scandinavians. Previous studies on the putative association between polymorphisms in the LTA, TNF and RAGE genes and micro-and macrovascular complications in type 2 diabetes have given conflicting results [14]-[20], [25]-[30]. Differences in study design, insufficient power and inclusion of different ethnic groups might explain some of the observed differences, as would inclusion of type 2 diabetic patients with LADA [30]. To circumvent this problem we excluded adult patients who were GAD antibody positive or required insulin therapy during the first year.
###end p 41
###begin p 42
###xml 352 355 352 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 414 417 414 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Knight1">[8]</xref>
###xml 586 590 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Yeh1">[31]</xref>
Some of the discrepancy in the published literature could also be due to the complex pattern of LD in the region. The HLA region on the short arm of chromosome 6 contains several genes involved in inflammatory responses. The haplotypic structure is complex and there is also a complex interaction between genes and gene products, as illustrated by the TNF gene polymorphism that can influence transcription of LTA [8], and receptor for advanced glycation end-products (RAGE), which after binding to its ligand can increase production of pro-inflammatory cytokines, among them TNF-alpha [31].
###end p 42
###begin p 43
###xml 55 58 55 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 60 72 60 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF and AGER</italic>
Taken together the data show that polymorphisms in the LTA, TNF and AGER genes increase risk of diabetic micro- and macroangiopathy either alone or together. Given the strong association with HLA-risk genotypes we can not rule out that they are part of a same haplotype and their risk on disease can therefore only be judged from studies assessing them all.
###end p 43
###begin title 44
Materials and Methods
###end title 44
###begin p 45
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Lindholm1">[13]</xref>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 353 356 351 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 372 375 368 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 551 555 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Noble1">[23]</xref>
###xml 634 638 628 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Single1">[24]</xref>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">Patients</span>
###xml 656 664 <span type="species:ncbi:9606">patients</span>
###xml 723 731 <span type="species:ncbi:9606">patients</span>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
###xml 1024 1032 <span type="species:ncbi:9606">patients</span>
###xml 1161 1169 <span type="species:ncbi:9606">patients</span>
###xml 1459 1467 <span type="species:ncbi:9606">patients</span>
A detailed description of study subjects and analytical methods has been given previously [13]. The study population was mainly the same as in the previous study. However, additional 98 type 1 and 796 type 2 diabetic patients were included and genotyped for the AGER -374T-->A polymorphism in this study and all the patients were also genotyped for the TNF -308 G-->A and LTA T60N C-->A polymorphisms. Patients were classified as having type 1 or type 2 diabetes by the attending physician using the World Health Organization (WHO) guidelines of 1985 [23] or, when diagnosed after January 1, 2001, according to the new WHO guidelines [24]. Type 1 diabetic patients with age at onset >35 years (N = 224) and type 2 diabetic patients positive for GAD antibodies (N = 197) were excluded. In addition, type 2 diabetic patients with an age at diagnosis <35 years and with permanent insulin treatment during the first year from diagnosis were excluded (N = 108). A total of 3699 (742 type 1 and 2957 type 2 diabetes) Scandinavian patients and 206 Scandinavian, non-diabetic control subjects were included in the study. Control subjects were selected among spouses of patients with hypertension; they were not allowed to have any first degree relatives with diabetes. No information on hypertension or myocardial infarction in non-diabetic control subjects was available. The Ethics committee of Malmo/Lund approved the study. Informed consent was obtained from all patients.
###end p 45
###begin title 46
Assessment of complications
###end title 46
###begin title 47
Diabetic nephropathy
###end title 47
###begin p 48
###xml 915 922 <span type="species:ncbi:9606">patient</span>
###xml 1012 1019 <span type="species:ncbi:9606">patient</span>
###xml 1068 1076 <span type="species:ncbi:9606">Patients</span>
###xml 1517 1525 <span type="species:ncbi:9606">patients</span>
###xml 1663 1671 <span type="species:ncbi:9606">patients</span>
###xml 1700 1708 <span type="species:ncbi:9606">patients</span>
The urinary albumin concentration was determined by immunonephelometry (Beckman Instruments, CA, USA) until 1998 and thereafter by an immunoturbimetric method (Beckman Coulter, Beckman Instruments, CA, USA). Albuminuria was reported either as microg/min (AER), mg/24 hours or as a urinary albumin/creatinine ratio (g/mol). Microalbuminuria was defined as 20-200 microg/min, 30-300 mg/24 hours or 2.0-25 in males and 2.8-25 g/mol in females. For the definition of microalbuminuria we also considered older values given as the urinary albumin concentration measured in a first morning specimen. Values of 30-300 mg/l were considered as microalbuminuria. Values above the upper limit were indicative of macroalbuminuria. Macroalbuminuria was considered present when at least two values above the cut-off limit for macroalbuminuria were recorded. One positive measurement only was considered as macroalbuminuria if the patient thereafter was treated with ACE inhibitors or angiotensin II receptor blockers or if the patient had had persistent microalbuminuria previously. Patients with other kidney diseases were excluded from the analysis. Normoalbuminuria required that all urinary albumin measurements were within the normal range, otherwise the albuminuria status was considered unknown. Duration of albuminuria was calculated from the onset of microalbuminuria when known, or from the latest measurement with no albuminuria. If not known (60% of all the cases with micro- or macroalbuminuria, 39% in type 1 diabetic patients) the duration was calculated from the first registered value of micro- or macroalbuminuria. When calculating the genotype frequencies in patients with normoalbuminuria, only patients with diabetes duration >/=10 years were included.
###end p 48
###begin title 49
Diabetic Retinopathy
###end title 49
###begin p 50
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 73 81 <span type="species:ncbi:9606">Patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
Information about the retinopathy status was available in 3072 patients. Patients were divided into two groups; subjects with no or non-proliferative retinopathy without macular edema and subjects with sight-threatening retinopathy, which included patients with proliferative retinopathy and/or photocoagulation treatment (panretinal and/or focal/grid for macular edema). The duration of sight-threatening retinopathy was defined from the first information of diagnosis or laser treatment. When calculating the genotype frequencies in patients without sight-threatening retinopathy only those with diabetes duration >/=10 years were included.
###end p 50
###begin title 51
Macrovascular disease
###end title 51
###begin p 52
###xml 249 257 <span type="species:ncbi:9606">patients</span>
Macrovascular disease was defined as previously diagnosed myocardial infarction, angina pectoris, transitory ischemic attack (TIA), stroke and/or peripheral vascular disease. Information on previous macrovascular disease was available in 93% of the patients.
###end p 52
###begin p 53
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
In logistic regression analysis age at diagnosis was used in stead of duration because the macrovascular disease duration was often unknown and sometimes a decade before the onset of diabetes. Lipid levels were not used in the regression analysis, because according to the clinical guidelines patients with previous episode of myocardial infarction or stroke should be treated with statins. Consequently, current cholesterol levels were lower in patients with previous episode of macrovascular disease and we did not have access to historical data.
###end p 53
###begin title 54
Genotyping
###end title 54
###begin p 55
###xml 24 27 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 56 60 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 340 348 334 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 348 352 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Lindholm1">[13]</xref>
###xml 402 405 396 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 421 424 415 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 443 447 437 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 573 576 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 584 587 578 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 598 602 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 231 238 <span type="species:ncbi:9606">patient</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 604 612 <span type="species:ncbi:9606">patients</span>
T60N C-->A (rs1041981), TNF -308 G-->A (rs1800629), and AGER -374 T-->A (rs1800624) polymorphisms were genotyped using the allelic discrimination method on the ABI 7900 instrument (Applied Biosystems, Foster City, CA). A subset of patient (629 type 1 and 1108 type 2 diabetic patients and all control subjects were previously genotyped for HLA-DQB1[13]. The genotyping success rates were 99.0% for the LTA, 98.7% for the TNF and 98.4% for the AGER polymorphisms. Re-genotyping was performed in a separate analysis in random samples from those which passed. A total of 226 (LTA), 234 (TNF) and 225 (AGER) patients were re-genotyped with a 100% genotyping concordance rate.
###end p 55
###begin title 56
Statistical analysis
###end title 56
###begin p 57
###xml 72 74 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 77 79 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 921 925 919 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Barrett1">[32]</xref>
###xml 1041 1044 1039 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1046 1049 1044 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 1054 1058 1052 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 1129 1133 1127 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Purcell1">[33]</xref>
###xml 1158 1162 1156 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002546-Kalinowski1">[34]</xref>
###xml 1231 1239 <span type="species:ncbi:9606">patients</span>
Data are presented as mean+/-SD or as median and interquartile range [25th-75th]. Chi-square test was used to test for frequency differences between studied genotypes. To test differences between group means, the Student's two-tailed t-test was used for normally distributed values and Mann-Whitney U-test for non-normally distributed medians. In order to assess factors associated with diabetic nephropathy, retinopathy and macrovascular disease, a multiple logistic regression analysis with forward selection was performed. All data were analysed with a NCSS 2004 (NCSS statistical software, Kaysville, UT, USA). A p-value <0.05 was considered statistically significant. To evaluate putative haplotype blocks, linkage disequilibrium (LD) between the SNPs was analyzed using Haploview 3.32 and D' values were calculated with 95% confidence intervals (CI) when the genotype frequencies were in Hardy-Weinberg equilibrium [32]. A corrected p-value was obtained after 100,000 permutations of individual SNPs and haplotype blocks including the TNF, LTA and AGER polymorphisms. Power analysis was made using Genetic Power calculator [33]. HW-QuickCheck software [34] was used for testing of putative excess of heterozygous/ homozygous patients.
###end p 57
###begin title 58
Power calculations
###end title 58
###begin p 59
###xml 198 201 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 203 206 199 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 211 215 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGER</italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
Power assuming alpha = 0.05 and relative risk of 1.3 was 11%, 31% and 32% for type 1 diabetic patients and 62%, 81% and 80% for type 2 diabetic patients with or without diabetic nephropathy for the LTA, TNF and AGER polymorphisms. The power for retinopathy was 68%, 86% and 85% in type 1 and 58%, 73% and 73% in type 2 diabetes and for macrovascular disease 20%, 28% and 28% in type 1 and 97%, 99% and 99% in type 2 diabetes.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
Role of inflammation in diabetic complications.
###end article-title 61
###begin article-title 62
Suppression of diabetic retinopathy with angiopoietin-1.
###end article-title 62
###begin article-title 63
A central role for inflammation in the pathogenesis of diabetic retinopathy.
###end article-title 63
###begin article-title 64
###xml 90 98 <span type="species:ncbi:9606">patients</span>
TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients.
###end article-title 64
###begin article-title 65
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes.
###end article-title 65
###begin article-title 66
Pathophysiology of coronary artery disease.
###end article-title 66
###begin article-title 67
Tumor necrosis factor locus: genetic organisation and biological implications.
###end article-title 67
###begin article-title 68
In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading.
###end article-title 68
###begin article-title 69
Glycoxidation: the menace of diabetes and aging.
###end article-title 69
###begin article-title 70
###xml 89 95 <span type="species:ncbi:9606">people</span>
Increased frequency of HLA A2/DR4 and A2/DR8 haplotypes in young saskatchewan aboriginal people with diabetic end-stage renal disease.
###end article-title 70
###begin article-title 71
###xml 60 68 <span type="species:ncbi:9606">patients</span>
HLA-DQB1*0201/0302 is associated with severe retinopathy in patients with IDDM.
###end article-title 71
###begin article-title 72
Lp(a) lipoprotein and HLA-DR genotype in early coronary artery disease.
###end article-title 72
###begin article-title 73
###xml 127 135 <span type="species:ncbi:9606">patients</span>
The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients.
###end article-title 73
###begin article-title 74
###xml 124 132 <span type="species:ncbi:9606">patients</span>
The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.
###end article-title 74
###begin article-title 75
Correlation between a gene polymorphism of tumor necrosis factor-alpha (G/A) and end-stage renal disease: a pilot study from north India.
###end article-title 75
###begin article-title 76
Tumor necrosis factor allelic polymorphism with diabetic retinopathy in India.
###end article-title 76
###begin article-title 77
TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction.
###end article-title 77
###begin article-title 78
The -308 G/A tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina.
###end article-title 78
###begin article-title 79
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction.
###end article-title 79
###begin article-title 80
Effects of lymphotoxin-alpha gene and galectin 2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules, and risk of coronary heart disease.
###end article-title 80
###begin article-title 81
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
A combination of human leukocyte antigen DQB1*02 and the tumor necrosis factor alpha promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes.
###end article-title 81
###begin article-title 82
###xml 261 269 <span type="species:ncbi:9606">patients</span>
The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T>C promoter polymorphism of receptor of the advanced glycation endproduct (RAGE) gene. Haplotype-independent association of the -429C allele with high hemoglobin(A1C) levels in diabetic patients.
###end article-title 82
###begin article-title 83
The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families.
###end article-title 83
###begin article-title 84
###xml 34 41 <span type="species:ncbi:9606">patient</span>
Haplotype frequency estimation in patient populations: the effect of departures from Hardy-Weinberg proportions and collapsing over a locus in the HLA region.
###end article-title 84
###begin article-title 85
Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy.
###end article-title 85
###begin article-title 86
The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes.
###end article-title 86
###begin article-title 87
-374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis.
###end article-title 87
###begin article-title 88
Gene polymorphisms in the TNF locus and the risk of myocardial infarction.
###end article-title 88
###begin article-title 89
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Association between tumour necrosis factor-alpha G-308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients.
###end article-title 89
###begin article-title 90
Large-scale studies of the association between variation at the TNF/LTA locus and susceptibility to type 2 diabetes.
###end article-title 90
###begin article-title 91
Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion.
###end article-title 91
###begin article-title 92
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 92
###begin article-title 93
Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.
###end article-title 93
###begin article-title 94
hw-quickcheck: an easy-to-use computer program for checking genotypes for agreement with Hardy-Weinberg expectations.
###end article-title 94
###begin p 95
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 95
###begin p 96
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by Skane County Council Research and Development Foundation and the Medical Research Council of Lundberg.
###end p 96

